Cardiovascular disease and COVID-19: les liaisons dangereuses
Open Access
- 11 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 27 (10) , 1017-1025
Abstract
Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.Keywords
This publication has 47 references indexed in Scilit:
- Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysisBMJ, 2012
- Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate StudyThe Journal of Infectious Diseases, 2011
- Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study*Critical Care Medicine, 2011
- An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006Epidemiology and Infection, 2010
- Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort StudyPLOS ONE, 2009
- Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of StatinsChest, 2007
- Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventionsClinical Science, 2007
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)Thorax, 2003
- Coronary Plaque DisruptionCirculation, 1995